CPIX - Cumberland Pharmaceuticals Inc.
| Previous Close | 3.6700 |
| Open | 3.5700 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.5700 - 3.7000 |
| 52 Week Range | 3.3200 - 6.9900 |
| Volume | 8,301 |
| Avg. Volume | 12,017 |
| Market Cap | 55.108M |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | May 11, 2020 - May 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.75 |
- Thomson Reuters StreetEvents
Edited Transcript of CPIX earnings conference call or presentation 18-Mar-20 8:30pm GMT
Q4 2019 Cumberland Pharmaceuticals Inc Earnings Call
- PR Newswire
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, today announced a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 coronavirus.
- Zacks
Cumberland Pharmaceuticals (CPIX) Q4 Earnings and Revenues Beat Estimates
Cumberland (CPIX) delivered earnings and revenue surprises of 800.00% and 20.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and full year 2019 financial results. Net Revenues for the fourth quarter were $13.7 million, and for the full year 2019, Net Revenues totaled $47.5 million, a 17% increase over the prior year.
- ACCESSWIRE
Cumberland Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, ...
- PR Newswire
Caldolor® Demonstrates Favorable Safety Profile In Newborns
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced topline results from a clinical study evaluating the safety and pharmacokinetics of Caldolor® (ibuprofen) Injection in children ranging from birth to six months of age. Topline results from this study indicate that Caldolor was well tolerated overall in this patient population, with no safety concerns noted.
- Zacks
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q4 Earnings Expected to Decline
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Cumberland Pharmaceuticals Reschedules Fourth Quarter And Annual 2019 Financial Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today the rescheduling of its fourth quarter and annual 2019 financial results and company update from Wednesday, March 11, 2020 to Wednesday, March 18, 2020 after market close. A conference call and live Internet webcast will be held on Wednesday, March 18, at 4:30 p.m. Eastern Time to discuss the results.
- PR Newswire
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2019 financial results and company update after the market closes on Wednesday, March 11, 2020. A conference call and live Internet webcast will be held on Wednesday, March 11, at 4:30 p.m. Eastern Time to discuss the results.
- PR Newswire
Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with a focus on hospital acute care, today announced the launch of Caldolor® (ibuprofen) Injection in a ready-to-use bag that may be administered without dilution for pain relief. This launch follows FDA approval in 2019 of the product's new delivery method.
- Thomson Reuters StreetEvents
Edited Transcript of CPIX earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Cumberland Pharmaceuticals Inc Earnings Call
- PR Newswire
Cumberland Pharmaceuticals To Hold Update Call To Discuss Recent Major Developments
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will hold an update call to discuss recent developments and plans for the Company's Caldolor® and RediTrexTM brands after the market closes on Tuesday, January 7, 2020. Cumberland will also give 2020 financial guidance during the call. A conference call and live Internet webcast will be held on Tuesday, January 7, at 4:30 p.m. Eastern Time to discuss the results.
- Insider Monkey
Cumberland Pharmaceuticals, Inc. (CPIX): Hedge Funds In Wait-and-See Mode
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX). Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) shares haven't […]
- Zacks
New Strong Sell Stocks for December 4th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- PR Newswire
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products.
- PR Newswire
New Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new online publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes that resulted from treating multiple infection types with Vibativ®, including complicated skin and skin structure infections (cSSSI), bone and joint infections, bacteremia and endocarditis, and lower respiratory tract infections (LRTI).
- PR Newswire
Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter
NASHVILLE, Tenn. , Nov. 12, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced ...
- Zacks
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.
- Zacks
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
- Zacks
Cumberland Pharmaceuticals (CPIX) to Report Q3 Results: Wall Street Expects Earnings Growth
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Cumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results
NASHVILLE, Tenn. , Nov. 5, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2019 financial results after the market closes on Tuesday, ...
- Simply Wall St.
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.
- PR Newswire
New Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia
NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Cumberland manufactures and distributes telavancin under the brand name Vibativ®. Vibativ® (telavancin) is a patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia.
